Clinical trials: Multiple Dose
Healthy, Sickle Cell Anemia
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, and pharmacokinetics of PF-07209326 in…
- Trial name
- NCT04255875
- Testing
- PF-07209326
- Where
- 16 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers
The purpose of this study is to evaluate the drug-drug interaction and safety between HCP1306, RLD2302 and RLD2102 in healthy volunteers.
- Trial name
- NCT06518122
- Testing
- HCP1306, RLD2302, RLD2102
- Where
- South Korea
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers
The purpose of this study is to investigate the pharmacokinetics, safety and tolerability of digoxin with and without co-administration of BI 1356.
- Trial name
- NCT02183402
- Testing
- Digoxin, BI 1356
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Rhizomelic Chondrodysplasia Punctata
A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics
PPI-1011 is being developed as a docosahexaenoic acid (DHA) containing plasmalogen precursor with good long-term stability, specifically for the treatment of rhizomelic chondrodysplasia punctata (RCDP), which is an ultra rare…
- Trial name
- NCT05969977
- Testing
- PPI-1011
- Where
- Canada
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- MED-LIFE DISCOVERIES LP
Healthy Subjects
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects
This study is a first-in-human, randomized, placebo-controlled, 4-part, single ascending dose and multiple ascending dose study.
- Trial name
- NCT04488900
- Testing
- CKD-508 Capsule, CKD-508 Tablet
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Alzheimer's Disease (AD)
Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients
This study is testing a new investigational drug called 8M2D to learn whether it is safe and well-tolerated in humans. 8M2D has not previously been given to people.
- Trial name
- NCT07568041
- Testing
- 8M2D
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Cenna Biosciences Inc.
Healthy Volunteers
Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045
Phase I, single-center, randomized, double-blind, placebo-controlled, multiple ascending dose (MAD), study to evaluate the safety/tolerability and pharmacokinetics (PK) of FP-045 administered to normal health volunteers (NHVs).
- Trial name
- NCT03686930
- Testing
- Cohort 1 - FP-045 oral solution, Cohort 2 - FP-045 oral solution, Cohort 3 - FP-045 oral solution
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Healthy
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Midazolam in the Blood
The main objective of this trial is to investigate the induction effect of multiple doses of BI 1015550 on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.
- Trial name
- NCT05550636
- Testing
- BI 1015550, midazolam
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Inflammatory Gastrointestinal Diseases
A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
Interleukin (IL)-6 is a cytokine produced in response to infection and tissue damage. IL-6 is believed to act as a key mediator in chronic inflammation and autoimmune diseases such as inflammatory bowel diseases.
- Trial name
- NCT06298032
- Testing
- Olamkicept Part A, Olamkicept Part B
- Where
- Germany
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Ferring Pharmaceuticals
Atopic Dermatitis
HL-300 Ointment in Healthy Volunteers
To evaluate the safety and tolerability of HL-300 ointment following single and multiple topical administrations in healthy Chinese adult volunteers.
- Trial name
- NCT07684937
- Testing
- HL-300
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Healthy Volunteers, Alzheimer Disease
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
This study involves single and multiple doses of LY3202626 and will evaluate the effects of LY3202626 on the body. There will be 4 parts to this study.
- Trial name
- NCT02323334
- Testing
- LY3202626, Itraconazole
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Food Effect, Healthy
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating females. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part…
- Trial name
- NCT03150498
- Testing
- BTD-001
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Balance Therapeutics
Diabetes
A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes
The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes
- Trial name
- NCT04855292
- Testing
- TG103 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Antitrypsin Deficiency Liver Disease
A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients with ZZ Type Alpha-1 Antitrypsin Deficiency…
- Trial name
- NCT02503683
- Testing
- ALN-AAT, Sterile Normal Saline (0.9% NaCl)
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Dental Caries
Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects
The purpose of the clinical study is to evaluate the safety and bacterial impact of study drug (C16G2) administered in multiple oral gel doses to adolescent and adult dental subjects.
- Trial name
- NCT02509845
- Testing
- C16G2
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Armata Pharmaceuticals, Inc.
Healthy Subjects
The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects
This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in Chinese healthy subjects
- Trial name
- NCT04880512
- Testing
- SYHX 1901 tablets
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Parkinson's Disease
A Study of Single and Multiple Doses of KW-6356 in Healthy Subjects
Phase I study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of KW-6356 in healthy volunteers
- Trial name
- NCT03830528
- Testing
- KW-6356 Low Dose, KW-6356 Middle Dose, KW-6356 High Dose
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
First-in-human Study of MRT-6160 in Healthy Subjects
The principal aim of this study is to obtain safety and tolerability data when MRT-6160 is administered orally as single and multiple doses to healthy subjects.
- Trial name
- NCT06597799
- Testing
- MRT-6160
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Monte Rosa Therapeutics, Inc
Safety Issues
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.
- Trial name
- NCT03473236
- Testing
- GB002, Generic Dry Powder Inhaler
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.